Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ] . US FDA label
Kidney dosing: Glimepiride (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Start 1 or 2 mg once daily with breakfast; increase by 1 to 2 mg every 1 to 2 weeks; maximum 8 mg/day (label). Older adults: start 1 mg.
- CrCl 30–59 mL/min
- Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg.
- CrCl 15–29 mL/min
- Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg.
- CrCl <15 mL/min (not on dialysis)
- Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg. No separate advice for CrCl <15; hypoglycemia can be prolonged. Specialist judgment.
- Hemodialysis (intermittent)
- Not studied in dialysis; the label gives no dialysis dose. Removal by hemodialysis unlikely (over 99.5% protein-bound). Specialist input; prefer agents with lower hypoglycemia risk.
- Peritoneal dialysis
- Not studied; no dose in label. Specialist input. Metabolites accumulate in kidney impairment; risk of prolonged hypoglycemia (label 8.6, 12.3).
- CRRT
- No data. Specialist input; insulin usually preferred in acute illness.
- Dialyzable? Not stated; unlikely (protein binding over 99.5%; label).
- Monitoring Blood glucose (hypoglycemia, which can be prolonged), hemoglobin A1c, kidney function. Hold in acute illness with poor intake.
From the Glimepiride monograph (renalcarematters.com, reviewed).
Use: Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. US FDA label
Kidney dosing: Metformin (single-agent)Show full dosing details
- eGFR ≥60
- Usual dosing. Assess kidney function before starting and periodically (label).
- eGFR 30–59
- eGFR 45–59: usual dose; consider dose reduction if at high risk of lactic acidosis. eGFR 30–44: label advises not to start; if continuing, reduce to a maximum of 1,000 mg/day (KDIGO 2022; ADA-KDIGO 2022). Recheck eGFR every 3 to 6 months.
- eGFR 15–29
- Contraindicated (label). Stop if eGFR falls below 30.
- eGFR <15 (not on dialysis)
- Contraindicated (label).
- Hemodialysis (intermittent)
- Contraindicated (eGFR <30 per label).
- Peritoneal dialysis
- Contraindicated (eGFR <30 per label).
- CRRT
- Not appropriate; contraindicated in severe kidney impairment (label).
- Dialyzable? Yes: dialyzable with clearance up to 170 mL/min under good hemodynamic conditions; hemodialysis may help remove drug in suspected overdose (label).
- Monitoring eGFR before starting and at least periodically; more often in older adults. Stop before or at the time of iodinated contrast in at-risk patients per label. Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1).
From the Metformin monograph (renalcarematters.com, reviewed).
Use: Monotherapy and Combination Therapy ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14) ] . US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Film-coated tablet: 500 mg/15 mg/1 mg
- Tablet: 500 mg/15 mg/2 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Glimepiride + Metformin + Pioglitazone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Tri-SenzaMetformin hydrochloride + Pioglitazone (as hydrochloride) + Glimepiride | 500 mg/15 mg/1 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc. | DR-XY42996 | Nov 21, 2028 | |
Tripride-2Metformin Hydrochloride + Pioglitazone ( as Hydrochloride) + Glimepiride | 500 mg/15 mg/2 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & burk Philippines Inc.Importer: Brown & Burk Philippines inc. | DRP-12941 | Oct 2, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
